QuickView for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=86A2AA8A39E51C0F450049D37E597C04;jsessionid=C1188DFB6C25D0C9A6AAC30CD302840A;jsessionid=248F3DAA0A3B49CFFA500CD72A63A70F;jsessionid=7DCB1D2D5C088C7A35EC5C67FB5DDFA2;jsessionid=7AB0F09470C76EF81FF4CA17C38B053E;jsessionid=3F703D95099F86E08FD3296AE45AF495;jsessionid=628753FEC5FC03D78A2D8CF52C2922DE;jsessionid=5268BC78C987061990E75611757CF007 (gene)

1. Thymic stroma and TFII-I: towards new targeted therapies.
2. Proteomic analysis of SRF associated transcription complexes identified TFII-I as modulator of SRF f…
3. Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.
4. The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and dis…
5. Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII.

There were no clinical trials for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=86A2AA8A39E51C0F450049D37E597C04;jsessionid=C1188DFB6C25D0C9A6AAC30CD302840A;jsessionid=248F3DAA0A3B49CFFA500CD72A63A70F;jsessionid=7DCB1D2D5C088C7A35EC5C67FB5DDFA2;jsessionid=7AB0F09470C76EF81FF4CA17C38B053E;jsessionid=3F703D95099F86E08FD3296AE45AF495;jsessionid=628753FEC5FC03D78A2D8CF52C2922DE;jsessionid=5268BC78C987061990E75611757CF007